Hepatitis C - Interferon-free therapy did not increase the risk of liver cancer

Summary with commentary:

No Extra Liver Cancer Risk with Interferon-Free HCV Regimens
by Diana Swift, March 25, 2018
MedPage Today

Earlier suggestions not supported in retrospective study of 857 patients
Successful treatment of cirrhotic patients with hepatitis C virus (HCV) with direct-acting interferon (IFN)-free antiviral therapy did not increase the risk of incident hepatocellular carcinoma (HCC), researchers said, nor was it associated with increased nodule size or number in those diagnosed with HCC.
Continue reading: https://www.medpagetoday.com/gastroenterology/hepatitis/71969

Full-Text Article:

Accepted Manuscript

The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C & sustained viral response: role of the treatment regimen

Hamish Innes, Stephen T. Barclay , Peter C. Hayes, Andrew Fraser , John F. Dillon, Adrian Stanley, Andy Bathgate, Scott A McDonald, David Goldberg, Heather Valerio, Ray Fox, Nick Kennedy, Pete Bramley, Sharon J. Hutchinson

LAY SUMMARY: We examined the risk of liver cancer among 857 patients with cirrhosis in Scotland who received hepatitis C antiviral therapy and achieved a cure. We compared the risk of first-time liver cancer in patients treated with the newest interferon-free regimens, to patients treated with interferon. After accounting for the different characteristics of these two treatment groups, we found no evidence that interferon-free therapy is associated with a higher risk of liver cancer.

Full text article shared by Henry E. Chang via twitter, view article here....